This has led to the development and investigation of several incretin-related therapies such as unimolecular GLP-1/glucagon receptor dual agonists, GLP-1/gastric inhibitory polypeptide (GIP) dual agonists and GLP-1/GIP/glucagon receptor triple agonists
27, 2026: Mounjaro may lead to greater lean body mass loss than Ozempic Yes, the GLP-1 drug semaglutide is available as a once-daily pill
Then there are other safety issues
Recovery can take six to eight weeks or more, depending on the type and extent of the surgery
The semaglutide segment dominated the market with a major share of 46% in 2025 because of its robust clinical efficacy in glycemic control and weight loss, which is backed by a wealth of empirical data
Yes, and we often do, since coordinated care tends to serve patients best